- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00909207
Patient-Reported Outcomes Version of Common Terminology Criteria (CTCPRO) Cognitive Debriefing
Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
The scientific aim of this study is to evaluate patient comprehension of the 77 newly developed items as well as the extent to which the items correspond to the concepts of interest for each patient reported outcome (PRO).
A secondary aim of this study is to evaluate the usability of the technology interface for collecting the PRO data of the PRO-CTCAE system once it has been built to accommodate the learning garnered during the cognitive interviews.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening:
The study staff will talk to your doctor or nurse, and/or look at your medical record, to see if you are currently receiving treatment. The study staff will also look at your medical record to see if you have any future clinic visits at M. D. Anderson. This is the first step of "screening" to help the researchers decide if you are eligible to take part in this study.
If you are found to be possibly eligible to take part in this study based on the first step of screening, the second step of screening will occur:
At your clinic visit, the study staff will talk to you about this study. You will be asked questions about school, which should take about 2 minutes.
Study Visit If you are found to be eligible and you agree to take part in this study, you will look at a list of 34 cancer symptoms if you are a male or a list of 36 cancer symptoms if you are a female. You will fill out a questionnaire that asks you to mark each symptom that you may be experiencing at this time, and other information about the symptoms such as how often they occur.
After you complete the questionnaire, you will be interviewed by the study staff about how you answered some of the questions. For example, you will be asked if the words describing the symptoms were easy to understand or if other words may be more clear.
There are no right or wrong answers to any part of this study. Researchers are interested in your thoughts about the words.
Filling out the questionnaire will take about 10-15 minutes. The interview will take about 20-30 minutes.
Study Data:
The interview will be audio-recorded. Only the study staff will hear the recording. The recording will be saved on a password-protected computer that can only be accessed by the study staff.
Your responses will be coded without using your name or other personal identifying information. Only the study staff will have access to the code numbers and be able to identify you.
Your responses will not be shared with your doctor without your consent.
In some of the questions, you will be asked about your feelings (for example, whether you feel unhappy or anxious). If your responses show that you may be having emotional difficulties, you will be given a list of community agencies that provide services for emotional issues. You may also speak to your doctor about your feelings.
Length of Study:
After the study visit, your active participation will be over. In some cases, the study staff may call you to ask that you clarify some of your answers. Your medical record may also be checked to confirm the cancer diagnosis and your treatments.
This is an investigational study. Up to 100 patients will take part in this study. Up to 20 will be enrolled at M. D. Anderson.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27708
- Duke University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- UT MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients must be aged 18 and over
- Able to read and understand English
- Patients with a high school education or less
- Patients who are undergoing chemotherapy or radiotherapy with curative or palliative intent.
- Patient is able to provide informed consent.
- All types of cancer diagnosis
Exclusion Criteria:
1) Significant cognitive impairment as determined by research staff's judgment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Interview
Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
|
Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comprehension of Patient Reported Outcome (PRO) Criteria
Time Frame: 1 day
|
The primary assessment tool will be the cognitive interview protocol.
|
1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Tito Mendoza, PhD, MS, MED, UT MD Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-0182
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Diseases
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
University of Colorado, DenverNot yet recruitingHematologic Malignancy | Pediatric Patients | Other Hematologic ConditionUnited States
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Innovent Biologics (Suzhou) Co. Ltd.Recruiting
-
Massachusetts General HospitalRecruiting
-
Fondazione EMN Italy OnlusCompletedHEMATOLOGIC MALIGNANCIESItaly
-
Center for International Blood and Marrow Transplant...National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedHematologic MalignancyUnited States
-
Rigshospitalet, DenmarkNovo Nordisk A/SCompletedHematologic MalignancyDenmark
-
SecuraBioCompletedHematologic MalignancyUnited States, Italy
Clinical Trials on Interview
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsCompleted
-
Centro Hospitalar Lisboa NorteUniversity of Lisbon; Faculdade de Psicologia e de Ciências de Educação da...Unknown
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Ohio UniversityNew York Blood CenterCompleted
-
University of New MexicoCompletedPregnancy TerminationUnited States
-
Dongzhimen Hospital, BeijingUnknown
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, FranceCompletedCancer | Elderly | Ethnographic Interview | Social Representation of Being Aged | Reasons of Non-participation in Clinical Trials | Qualitative MethodFrance
-
University Hospital, GrenobleRegional Council of Auvergne-Rhône-AlpesRecruitingTraumatic Brain InjuryFrance
-
Beth Israel Deaconess Medical CenterCompletedDyspepsia | Heartburn | Gastroesophageal Reflux Disease (GERD)United States
-
Northwestern UniversityRegeneron PharmaceuticalsCompletedPsoriasis | Atopic Dermatitis | IchthyosisUnited States